Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial crawled time : 20:00 save search
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
CLPT | $5.64 1.99% 17K
|
Health Technology
| Email alert
Add to watchlist
avb-101 first dementia for trial
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
Published: 2024-04-15 (Crawled : 20:00) - globenewswire.com
ORIC | $9.84 0.82% 130K
|
Health Technology
|
| O: -1.05%
H: 2.75%
C: 0.11%
oric-114 first pharmaceuticals expansion trial
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 34K
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
GILD | $65.99 -1.4% 1.9M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.8372 2.57% 3.5M
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
CRVS | $1.38 1.47% 43K
|
Health Technology
|
| O: 2.45%
H: 0.0%
C: -9.58%
dermatitis pharmaceuticals for trial
DOJ Senior Trial Counsel Amy Kossak Joins Ropes & Gray's Government Enforcement Team
Published: 2024-04-09 (Crawled : 20:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
| Email alert
Add to watchlist
trial
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
Published: 2024-04-09 (Crawled : 20:00) - prnewswire.com
FUSN | $21.23 -0.05% 72K
|
Health Technology
|
| O: -0.19%
H: 0.28%
C: 0.09%
fpi-2265 presentation pharmaceuticals meeting trial
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
Published: 2024-04-08 (Crawled : 20:00) - globenewswire.com
KA A | $0.489 4.04% 330K
|
Manufacturing
|
| O: -12.68%
H: 3.59%
C: -8.72%
vista-101 ongoing trial response
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Published: 2024-04-02 (Crawled : 20:00) - globenewswire.com
SGHT | $5.23 -2.79% 78K
|
|
| O: 6.8%
H: 2.07%
C: -9.98%
sciences meeting trial results
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
Published: 2024-03-28 (Crawled : 20:00) - globenewswire.com
CADL | $5.58 2.57% 280K
|
| Email alert
Add to watchlist
can-3110 drug presentation update trial therapeutics glioblastoma
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
Published: 2024-03-22 (Crawled : 20:00) - globenewswire.com
IVVD | $2.355 -5.04% 150K
|
Manufacturing
| Email alert
Add to watchlist
vyd222 trial
ROSEN, LEADING TRIAL ATTORNEYS, Encourages iRobot Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - IRBT
Published: 2024-03-20 (Crawled : 20:00) - prnewswire.com
BTAFF | $28.176 1.8K
|
Consumer Non-Durables
|
| O: -3.87%
H: 0.0%
C: -1.14%
BTI | $28.695 0.37% 1.4M
|
Consumer Non-Durables
|
| O: -2.13%
H: 0.26%
C: -0.56%
IRBT | News | $7.46 6.12% 400K
|
Consumer Durables
|
| O: 0.81%
H: 2.88%
C: -3.11%
AMZN | $182.225 0.52% 9.7M
|
Retail Trade
|
| O: 1.03%
H: 0.79%
C: -1.02%
corporation deadline trial
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
Published: 2024-03-13 (Crawled : 20:00) - globenewswire.com
IVA | $3.28 1.86% 6.7K
|
Health Technology
|
| O: 1.27%
H: 1.5%
C: 0.25%
trial results
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Palo Alto Networks, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PANW
Published: 2024-03-12 (Crawled : 20:00) - prnewswire.com
XPOF | News | $13.1 -0.61% 150K
|
|
| O: 0.59%
H: 2.21%
C: -1.89%
PANW | News | $284.07 2.43% 1.2M
|
Electronic Technology
|
| O: 0.31%
H: 2.51%
C: 1.58%
IRBT | News | $7.46 6.12% 400K
|
Consumer Durables
|
| O: -0.41%
H: 4.58%
C: -0.31%
deadline trial
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
Published: 2024-03-12 (Crawled : 20:00) - globenewswire.com
CRNX | $44.04 0.07% 140K
|
Health Technology
|
| O: 0.81%
H: 2.03%
C: -1.41%
positive treatment topline trial results
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
Published: 2024-02-22 (Crawled : 20:00) - globenewswire.com
COGT | $6.455 -1.15% 170K
|
Health Technology
|
| O: -1.12%
H: 0.45%
C: -15.93%
bezuclastinib positive trial
HII Completes Builder’s Trials On Richard M. McCool Jr. (LPD 29)
Published: 2024-02-01 (Crawled : 20:00) - globenewswire.com
HII | $273.26 0.75% 24K
|
Electronic Technology
|
| O: -0.65%
H: 1.22%
C: 0.91%
trials
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
Published: 2024-01-16 (Crawled : 20:00) - prnewswire.com
SRPT | $118.32 0.37% 65K
|
Health Technology
|
| O: -0.49%
H: 3.17%
C: 1.94%
RGNX | News | $16.67 -2.11% 150K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -7.15%
CLSD | $1.27 0.79% 86K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.94%
rgx-314 aaviate positive treatment trial
MedinCell’s partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI)
Published: 2024-01-09 (Crawled : 20:00) - biospace.com/
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
teva study
Lyndra Therapeutics Announces Positive Data from Pivotal Phase 3 Study with Oral Weekly Risperidone (LYN-005) for Schizophrenia
Published: 2024-01-04 (Crawled : 20:00) - biospace.com/
GILD | $65.99 -1.4% 1.9M
|
Health Technology
|
| O: 0.37%
H: 1.38%
C: 0.82%
lyn-005 positive schizophrenia therapeutics study
New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar
Published: 2024-01-03 (Crawled : 20:00) - biospace.com/
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: 0.46%
H: 2.02%
C: -3.53%
correlation
Gainers vs Losers
| 82% | 18% |
Top 10 Gainers
AGBA | $0.7995 99.88% 73M
|
Finance
BPTH | $6.21 91.67% 58M
|
Health Technology
INVO | $1.36 78.95% 3.6M
|
Health Technology
TIRX | $0.8258 70.34% 50M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
VTNR S | $1.295 32.25% 5.5M
|
Industrial Services
ALRN | $5.53 30.12% 250K
|
Health Technology
HOLO | $2.86 27.68% 28M
|
XPON | $2.43 25.91% 7.2M
|
Your saved searches
Save your searches and get alerts when important news are released.